| NCT05430958 | Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers | WITHDRAWN | PHASE1 | 2022-10 | 2024-03 | 2024-03 |
| NCT04588428 | Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers | COMPLETED | PHASE2 | 2021-06-21 | 2023-01-19 | 2023-01-19 |
| NCT04093076 | Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana | COMPLETED | PHASE1 | 2021-01-27 | 2022-10-14 | 2022-10-14 |
| NCT04642638 | Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure | TERMINATED | PHASE2, PHASE3 | 2020-11-30 | 2022-09-13 | 2022-09-13 |
| NCT04398433 | INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP) | COMPLETED | PHASE1, PHASE2 | 2020-06-15 | 2022-12-15 | 2022-12-15 |
| NCT04336410 | Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers | COMPLETED | PHASE1 | 2020-04-03 | 2022-02-10 | 2022-02-10 |
| NCT03805984 | Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers | COMPLETED | PHASE1 | 2019-05-09 | 2020-10-21 | 2020-10-21 |
| NCT03721978 | REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) | COMPLETED | PHASE3 | 2019-02-28 | 2022-09-15 | 2022-08-23 |
| NCT03491683 | INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2018-05-31 | 2025-12-31 | 2025-12-31 |
| NCT03502785 | INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma | COMPLETED | PHASE1, PHASE2 | 2018-05-24 | 2025-05-09 | 2025-05-09 |
| NCT03499795 | VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2 | COMPLETED | PHASE2 | 2018-05-15 | 2021-05-26 | 2020-06-16 |
| NCT03180684 | Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3) | COMPLETED | PHASE2 | 2017-08-31 | 2020-12-18 | 2020-07-23 |
| NCT03185013 | REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) | COMPLETED | PHASE3 | 2017-06-28 | 2021-04-06 | 2020-07-08 |
| NCT02514213 | Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer | COMPLETED | PHASE1 | 2015-07 | 2017-12-12 | 2017-12-12 |
| NCT02464670 | Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers | COMPLETED | PHASE1 | 2015-05 | 2018-05-24 | 2018-05-24 |
| NCT02431312 | Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects | COMPLETED | PHASE1 | 2015-01-12 | 2018-05-22 | 2018-05-22 |
| NCT02960594 | hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse | COMPLETED | PHASE1 | 2014-12 | 2018-11-09 | 2018-11-09 |
| NCT02163057 | Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma | COMPLETED | PHASE1, PHASE2 | 2014-08-13 | 2017-01-23 | 2017-01-23 |
| NCT02172911 | A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer | COMPLETED | PHASE1, PHASE2 | 2014-06-06 | 2017-09-07 | 2017-09-07 |
| NCT02241369 | Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies | COMPLETED | PHASE1 | 2014-05 | 2018-09 | 2018-09 |
| NCT01403155 | A Follow-On Study With an H5 Influenza Vaccine for Subjects Who Participated in Study FLU-001 | COMPLETED | PHASE1 | 2011-05 | 2012-08 | 2012-08 |
| NCT01405885 | A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza Virus | COMPLETED | PHASE1 | 2011-05 | 2013-08 | 2013-08 |
| NCT01304524 | A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3 | COMPLETED | PHASE2 | 2011-04 | 2015-04 | 2014-05 |
| NCT01082692 | Study of PENNVAXâ„¢-B (Gag, Pol, Env) + Electroporation in HIV-1 Infected Adult Participants | COMPLETED | PHASE1 | 2011-01 | 2012-08 | 2012-08 |
| NCT01188850 | Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult Females Previously Vaccinated With Three Doses of VGX-3100 | COMPLETED | PHASE1 | 2010-07 | 2011-10-20 | 2011-10 |
| NCT01142362 | Study of VGX-3400X, H5N1 Avian Influenza Virus DNA Plasmid + Electroporation in Healthy Adults | COMPLETED | PHASE1 | 2010-06 | 2011-11 | 2011-11 |
| NCT00685412 | Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3 | COMPLETED | PHASE1 | 2008-05 | 2011-03 | 2011-01 |
| NCT00198328 | Medpulser Electroporation With Bleomycin Study to Treat Posterior Head and Neck Squamous Cell Carcinoma | TERMINATED | PHASE3 | 2004-11 | 2007-06 | 2007-06 |
| NCT00198315 | Medpulser Electroporation With Bleomycin Study to Treat Anterior Head and Neck Squamous Cell Carcinoma | TERMINATED | PHASE3 | 2004-06 | 2007-06-01 | 2007-06 |
| NCT00198276 | Study Using the MedPulser Electroporation System With Bleomycin to Treat Cutaneous and Subcutaneous Cancer | COMPLETED | PHASE4 | 2004-02 | 2008-09 | 2008-09 |
| NCT00198263 | Study Using the Medpulser Electroporation System With Bleomycin to Treat Head and Neck Cancer | COMPLETED | PHASE4 | 2004-01 | 2008-09 | 2008-09 |